Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Breast cancer chemotherapy drug Adriamycin doubted while Herceptin praised

  • Comment

The validity of chemotherapy drug Adriamycin has been called into question, as a new study shows breast cancer survival rates are almost unchanged by its usage.

The study, published in the New England Journal of Medicine, found the survival rates between those who were given the drug and those who were not were so similar, it was not needed to treat the disease at all.

Instead, researchers found combining chemotherapy and the drug Herceptin to treat women with an aggressive form of early-stage breast cancer could help boost survival rates.

The study showed that those who took a combination of Adriamycin, Herceptin and chemotherapy drugs Carboplatin and Taxotere had a five-year survival rate of 92%.

Meanwhile, 91% of those who took Herceptin, Carboplatin and Taxotere, but no Adriamycin, were still alive after five years. Combining Adriamycin and Herceptin has been shown to cause permanent heart damage.

Dennis Slamon, of the University of California, lead author of the study, said: “We’re encouraged that the survival advantages found in this study have been maintained and continue to be significant.

“I believe there’s room for even further improvement.”

 

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.